No Data
BofA Securities Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $24
Perspective Therapeutics Price Target Announced at $21.00/Share by Truist Securities
Truist Financial Initiates Perspective Therapeutics(CATX.US) With Buy Rating, Announces Target Price $21
Express News | Perspective Therapeutics: Aggregate Consideration for Such Equipment & Services Under Deal Is About EUR 49 Mln Payable in Cash
Express News | Perspective Therapeutics: On Sept 18, Entered Into Master Equipment and Services Agreement & Statements of Work Thereunder With Comecer Spa
Perspective Therapeutics Presents at the World Molecular Imaging Congress 2024